Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
122 hedge funds and large institutions have $1.48B invested in Spark Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 7 closing their positions.
915% more call options, than puts
Call options by funds: $3.81M | Put options by funds: $375K
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more capital inflows, than outflows
Capital inflows: $236M | Capital outflows: $118M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3% more funds holding
Funds holding: 119 → 122 (+3)
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
0.37% less ownership
Funds ownership: 90.05% → 89.68% (-0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$108M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.7M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$17.6M |
| 5 |
PointState Capital
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$34.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.6M |
| 3 |
SMV
Sofinnova Management VIII
Menlo Park,
California
|
-$12.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$8.27M |
| 5 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$5.91M |
ONCE Hedge Fund Activity: Q1 2017 in Review
122 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q1 2017, worth a combined $1.48B — up 7.4% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ONCE positions and 7 closed out — a net gain of 9 holders — while 41 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $108M. The largest seller was Millennium Management, cutting an estimated $34.1M.
- 122 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q1 2017, up from 119 in Q4 2016.
- Funds reported $1.48B of Spark Therapeutics, Inc. Common Stock stock for Q1 2017, up 7.4% quarter-over-quarter.
- 16 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q1 2017 and 7 closed out, a net change of +9 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $108M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q1 2017 was Millennium Management, an estimated $34.1M sold.
Based on aggregated 13F filings for Q1 2017.